Monte Rosa Therapeutics, Inc. (GLUE) vs Henry Schein, Inc. (HSIC)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| GLUE | HSIC | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical Distribution |
| Size band | SMALL | MID |
| Listing | Nasdaq GS | Nasdaq GS |
| Country | United States | United States |
| Theme | oncology | dental-care |
| Price and returns | ||
| Last close | $10.48 | $84.51 |
| Return · 1 week | −1.69% | +0.64% |
| Return · 1 month | −10.50% | −1.72% |
| Return · 3 months | −52.45% | −1.40% |
| Return · year to date | −31.55% | +10.01% |
| Return · 1 year | −14.94% | +33.00% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −59.33% | −8.32% |
| 52-week high | $25.77 | $92.18 |
| 52-week low | $8.94 | $62.15 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $894.08M | $9.63B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $11.73M | $86.83M |
| Employees | 173 | 25,000 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 24.77× |
| Price to earnings · forward | n/a (negative forward earnings) | 14.17× |
| Price to sales | 30.59× | 0.71× |
| Price to book | 1.80× | 3.01× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | 13.60× |
| Enterprise value to revenue | 9.90× | 1.08× |
| PEG ratio | — | 1.69 |
| Earnings per share · trailing | -1.75 | 3.43 |
| Profitability | ||
| Gross margin | — | 31.32% |
| Operating margin | −547.84% | 5.76% |
| Profit margin | −560.85% | 2.96% |
| Return on equity | −42.66% | 8.85% |
| Return on assets | −21.63% | 4.39% |
| Growth | ||
| Revenue growth | −61.30% | +6.70% |
| Earnings growth | — | +17.10% |
| Balance sheet and payout | ||
| Debt / equity (%) | 7.80 | 80.73 |
| Current ratio | 10.58 | 1.32 |
| Dividend yield | 0.00% | 0.00% |
| Payout ratio | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 40.98 | 45.66 |
| ADX · 14 | 29.11 | 18.77 |
| 50-day average | $12.43 | $86.85 |
| 200-day average | $17.65 | $80.89 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 5.74% | 2.39% |
The full GLUE analysis
Everything this table leaves out for Monte Rosa Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the GLUE argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full GLUE analysisThe full HSIC analysis
Everything this table leaves out for Henry Schein, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the HSIC argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full HSIC analysis